drugset / Trial / NCT00249262
Taxoprexin Treatment for Advanced Skin Melanoma
NaSingle-groupOpen-labelTreatment
Summary
To evaluate objective response rate and duration of response to weekly Taxoprexin®. To evaluate the safety profile of weekly Taxoprexin® in this patient population. To evaluate overall survival in the same patient population. To evaluate time to disease progression, and the time to treatment failure in patients with metastatic malignant melanoma being treated with weekly Taxoprexin® Injection.
Timeline
- Start
- 2005-10
- Primary completion
- 2007-04
- Completion
- 2007-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PACLITAXEL DOCOSAHEXAENOIC ACID | Small molecule | 500 mg/m2 | Intravenous |